Evidence map›Paper›PMID 30078731›Full record

ArticleDevelopmental cell2018

FACT Sets a Barrier for Cell Fate Reprogramming in Caenorhabditis elegans and Human Cells.

Ena Kolundzic, Andreas Ofenbauer, Selman I Bulut, Bora Uyar, Gülkiz Baytek, Anne Sommermeier, Stefanie Seelk, Mei He, Antje Hirsekorn, Dubravka Vucicevic and 4 more

Abstract read
In one paragraph

Article in Developmental cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. High-Throughput Toxicity Screening withEnvironmental science & technology · 2026
    Review
  7. TheToxicology reports · 2025
    Article
  8. Article
  9. Analysis ofComputational and structural biotechnology journal · 2024
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ena KolundzicBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Andreas OfenbauerBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Selman I BulutBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Bora UyarBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Gülkiz BaytekBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Anne SommermeierBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Department of Biology, Humboldt University, 10115 Berlin, Germany.
Stefanie SeelkBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Mei HeBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Antje HirsekornBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Dubravka VucicevicBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Altuna AkalinBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.
Sebastian DieckeBerlin Institute of Health, 13125 Berlin, Germany. Electronic address: sebastian.diecke@mdc-berlin.de.
Scott A LacadieBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany; Berlin Institute of Health, 13125 Berlin, Germany. Electronic address: scott.lacadie@mdc-berlin.de.
Baris TursunBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany. Electronic address: baris.tursun@mdc-berlin.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chromatin regulator FACT (facilitates chromatin transcription) is essential for ensuring stable gene expression by promoting transcription. In a genetic screen using Caenorhabditis elegans, we identified that FACT maintains cell identities and acts as a barrier for transcription factor-mediated cell fate reprogramming. Strikingly, FACT's role as a barrier to cell fate conversion is conserved in humans as we show that FACT depletion enhances reprogramming of fibroblasts. Such activity is unexpected because FACT is known as a positive regulator of gene expression, and previously described reprogramming barriers typically repress gene expression. While FACT depletion in human fibroblasts results in decreased expression of many genes, a number of FACT-occupied genes, including reprogramming-promoting factors, show increased expression upon FACT depletion, suggesting a repressive function of FACT. Our findings identify FACT as a cellular reprogramming barrier in C. elegans and humans, revealing an evolutionarily conserved mechanism for cell fate protection.

Indexed as

Cellular ReprogrammingGene Expression RegulationAnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsCell DifferentiationCell LineageCells, CulturedChromatinDNA-Binding ProteinsFibroblastsHigh Mobility Group ProteinsHumansInduced Pluripotent Stem CellsTranscriptional Elongation FactorsTranscriptomeCaenorhabditis elegans ProteinsChromatinDNA-Binding ProteinsHigh Mobility Group ProteinsSSRP1 protein, humanTranscriptional Elongation FactorsC. eleganscell fate maintenancecell fate safeguardingchromatin remodelerfacilitates chromatin transcriptionFACThuman fibroblastsreprogramming

Identifiers

PMID30078731
PMCPMC6137076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.